sarcodon aspratus polysaccharides

**Sarcodon aspratus polysaccharides** are a heterogeneous natural-product mixture of polysaccharide fractions isolated from the edible mushroom *Sarcodon aspratus*. The published literature describes these preparations as preclinical bioactive polysaccharides with antioxidant, anti-inflammatory, immunomodulatory, microbiota-modulating, gastroprotective, anti-fibrotic, metabolic, and antitumor-associated effects in cell and animal models. Reported mechanisms are pathway-level rather than a validated single molecular target: studies describe activation of Nrf2 signaling, suppression of TLR4-driven inflammatory signaling, and inhibition of NF-kappaB, TGF-beta1, and MAPK pathway activity in disease models including pulmonary fibrosis, gastric ulcer, obesity-related metabolic dysfunction, chemotherapy toxicity, and in vitro tumor-cell growth assays. There is no evidence in the provided sources of an approved pharmaceutical product, clinical-stage development program, or standardized commercial drug formulation; the asset is best characterized as a preclinical mushroom-derived polysaccharide nutraceutical or natural-product research therapeutic concept rather than an established drug product.

Other names

sarcodon aspratus polysaccharidespolysaccharides from Sarcodon aspratusSarcodon aspratus polysaccharide